Healthcare Services

Molecular Tumor Board Solutions Market Future Outlook Showing Expansion Toward $2.86 Billion by 2030

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Molecular Tumor Board Solutions Market Expected To Change Between 2026 And 2030?

The market size for molecular tumor board solutions has experienced rapid expansion in recent years. This market is projected to expand from $1.53 billion in 2025 to reach $1.74 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.7%. Historically, this growth has been driven by factors such as the broadened scope of precision oncology programs, the greater accessibility of genomic sequencing data, the formation of more multidisciplinary cancer care teams, the increasing uptake of clinical decision support software, and enhanced data sharing capabilities among oncology centers.

The molecular tumor board solutions market size is projected to experience swift expansion in the coming years. Its valuation is anticipated to reach $2.87 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.4%. This anticipated growth during the forecast period can be ascribed to several factors, including heightened investments in personalized cancer treatment, an escalating demand for molecularly guided therapies, the wider adoption of cloud deployment within the healthcare sector, enhanced integration with clinical trial matching platforms, and the increasing incorporation of AI-driven oncology analytics. Key trends foreseen over this period encompass a greater utilization of AI-assisted variant interpretation, the deepening integration of multimodal genomic data, the proliferation of cloud-based tumor board platforms, an increasing uptake of collaborative decision support tools, and a sharpened emphasis on personalized oncology workflows.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28274&type=smp

Which Economic Or Industry Drivers Are Impacting The Molecular Tumor Board Solutions Market?

The expanding occurrence of cancer is projected to fuel the advancement of the molecular tumor board solutions market in the coming years. Cancer encompasses a range of illnesses defined by the unchecked proliferation and dissemination of atypical cells within the body. This surge in cancer cases stems from lifestyle factors, including inadequate nutrition, tobacco use, lack of physical activity, and heavy alcohol intake. Molecular tumor board solutions facilitate cancer management through expert, interdisciplinary analysis of patients’ genomic and clinical information, thereby allowing for tailored treatment approaches. These solutions improve clinical judgments by incorporating molecular profiling and insights generated by artificial intelligence, leading to better patient results and more precise treatments. For example, in February 2024, the World Health Organization, a global public health agency based in Switzerland, reported a forecast of over 35 million new cancer cases by 2050. This represents a 77% rise from the approximately 20 million cases estimated in 2022. Consequently, the growing incidence of cancer is propelling the expansion of the molecular tumor board solutions market.

How Is The Molecular Tumor Board Solutions Market Structured Across Different Segments?

The molecular tumor board solutions market covered in this report is segmented –

1) By Component: Software, Services

2) By Deployment Mode: On-Premises, Cloud-Based

3) By Application: Clinical Decision Support, Genomic Data Interpretation, Patient Management, Other Applications

4) By End-User: Hospitals, Cancer Centers, Research Institutes, Other End-Users

Subsegments:

1) By Software: Clinical Decision Support, Data Analytics, Reporting And Visualization, Integration Platforms

2) By Services: Consulting, Implementation, Training And Support, Maintenance And Upgrades

What Trends Are Affecting The Expansion Of The Molecular Tumor Board Solutions Market?

Leading companies within the molecular tumor board solutions market are concentrating their efforts on creating novel solutions, including molecular profiling tests, with the goal of improving the precision and efficacy of cancer diagnosis and treatment strategies. Molecular profiling tests function as diagnostic tools designed to examine a tumor’s genetic and molecular attributes, thereby informing tailored cancer treatment choices. An illustrative example occurred in April 2025, when Guardant Health Inc., a US-based firm specializing in biotechnology and precision oncology, introduced Guardant360 Tissue. This innovative molecular profiling test for tumor tissue incorporates extensive multiomic analysis, covering DNA, RNA, AI-powered PD-L1, and genome-wide methylation data. Utilizing the Guardant Infinity smart liquid biopsy platform, this sophisticated test offers a more thorough and multifaceted perspective on cancer, facilitating more detailed tumor classification and subtyping. Guardant360 Tissue provides results in less than two weeks, is eligible for Medicare coverage for qualifying patients, and seeks to advance precision oncology by furnishing more profound insights to guide therapeutic decisions, such as those involving poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapies.

Which Major Players Dominate The Molecular Tumor Board Solutions Market?

Major companies operating in the molecular tumor board solutions market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Illumina Inc., Novogene Co. Ltd., QIAGEN N.V., Myriad Genetics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Mayo Clinic Laboratories, Sectra AB, GenomOncology LLC, MedGenome Labs Ltd., Burning Rock Biotech Limited, NantHealth Inc., SOPHiA GENETICS SA, Variantyx Inc., Baylor Genetics, Molecular Health GmbH, PierianDx Inc., Oncompass Medicine, CureMatch Inc.

Read the full molecular tumor board solutions market report here:

https://www.thebusinessresearchcompany.com/report/molecular-tumor-board-solutions-global-market-report

What Are The Top-Performing Regions Within The Molecular Tumor Board Solutions Market?

North America was the largest region in the molecular tumor board solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular tumor board solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Molecular Tumor Board Solutions Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28274&type=smp

Browse Through More Reports Similar to the Global Molecular Tumor Board Solutions Market 2026, By The Business Research Company

Structural Biology And Molecular Modeling Techniques Global Market Report

https://www.thebusinessresearchcompany.com/report/structural-biology-and-molecular-modeling-techniques-global-market-report

Molecular Spectroscopy Global Market Report

https://www.thebusinessresearchcompany.com/report/molecular-spectroscopy-global-market-report

Small Molecule Api Global Market Report

https://www.thebusinessresearchcompany.com/report/small-molecule-api-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795